Systemic sclerosis.
Systemic sclerosis (SSc, scleroderma) is a complex autoimmune connective tissue disease driven by vascular injury, immune dysregulation, and fibrosis. It affects skin, blood vessels, lungs, GI tract, heart, and kidneys. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are leading causes of mortality — which is why screening with PFTs and echocardiography is so important. Modern treatments (mycophenolate, nintedanib, tocilizumab, PAH-targeted therapy) have changed outcomes dramatically. Exercise is disease-modifying medicine.
The mechanism, the vasculopathy-fibrosis cascade.
SSc is one of the most clinically complex autoimmune diseases. Four mechanisms drive what patients experience:
Vasculopathy
Endothelial dysfunction and small-vessel injury come first — manifesting as Raynaud's, digital ulcers, and pulmonary hypertension. The vascular disease often precedes the fibrosis by years.
Autoimmunity
Anti-Scl-70 (anti-topoisomerase) and anti-RNAP3 antibodies predict diffuse cutaneous disease and ILD or renal crisis. Anti-centromere predicts limited cutaneous disease and PAH. The antibody profile tells you what to screen for.
Fibroblast activation
Activated fibroblasts overproduce collagen, causing the skin tightening that defines SSc and the fibrosis that scars the lungs (ILD), heart, and GI tract.
Multi-organ involvement
Skin is just where you see it. GI dysmotility, ILD, PAH, renal crisis, and cardiac fibrosis are the prognostically important manifestations. Screening is everything.
The 4-step plan, applied to SSc.
Get the right diagnosis
ANA, ENA panel (anti-Scl-70, anti-centromere, anti-RNAP3), nailfold capillaroscopy (the cheapest, most useful early test), modified Rodnan skin score for skin involvement, PFTs with DLCO (baseline plus annual), echocardiogram with TR jet (baseline plus annual for PAH screening), HRCT chest at baseline. ACR/EULAR 2013 criteria.
Learn more about labs →Clean up your food
Small frequent meals if dysphagia or early satiety. Elevate the head of the bed for GERD. Avoid foods that worsen reflux (chocolate, mint, caffeine, fatty foods, alcohol). Mediterranean pattern fits well with the small-meal approach.
SSc & diet →Detox your daily life
Silica and organic solvent exposure are well-established environmental triggers — occupational history matters in evaluation. Cold protection is essential for Raynaud's. Smoking cessation is non-negotiable.
SSc & environment →Build a stronger body
The G-FoRSS framework (Saketkoo 2021) outlines exercise as disease-modifying medicine across five domains: pulmonary, vascular, musculoskeletal, fatigue, and quality of life. Hand mobility work prevents contractures. Aerobic exercise preserves cardiopulmonary capacity in ILD.
SSc & exercise →
Go deeper.
Common misconceptions.
"Scleroderma is just a skin condition."
Skin is where you see SSc, but it's not what kills patients. ILD and PAH are the leading causes of mortality. Renal crisis and cardiac involvement also matter. Diffuse cutaneous SSc and limited cutaneous SSc have very different organ patterns — knowing your subtype matters.
"There's nothing to do besides manage symptoms."
The landscape has changed dramatically. Mycophenolate and nintedanib are evidence-based for SSc-ILD. Tocilizumab has skin and lung data. PAH-targeted therapy (PDE5 inhibitors, ERAs, prostacyclin analogs) extends survival in SSc-PAH. The era of 'nothing to do' is over.
"Exercise is dangerous when you have lung involvement."
The G-FoRSS position paper frames exercise as disease-modifying medicine — including in patients with ILD. Supervised pulmonary rehabilitation improves outcomes. Avoidance is the trap, not movement.
When to see a rheumatologist.
See a rheumatologist if you have:
- Raynaud's phenomenon plus a positive ANA
- Skin tightening of the fingers, hands, or face
- Severe GERD plus Raynaud's
- Unexplained shortness of breath plus Raynaud's
- Digital ulcers or pitted scars on fingertips
- Telangiectasias on face, hands, or chest
- Calcinosis (calcium deposits under the skin)
- Family history of SSc or other CTD plus Raynaud's
Raynaud's with abnormal nailfold capillaries plus a SSc-specific antibody is highly predictive of evolving SSc — early referral is critical because organ screening starts at diagnosis.
- van den Hoogen F, et al. 2013 ACR/EULAR classification criteria for systemic sclerosis. Ann Rheum Dis, 2013. PubMed 24122180
- Saketkoo LA, et al. Exercise as disease-modifying medicine in systemic sclerosis: G-FoRSS position paper. Best Pract Res Clin Rheumatol, 2021. PMC8478716
- Distler O, et al. Nintedanib for SSc-ILD: SENSCIS trial. N Engl J Med, 2019. PubMed 31112379
- Khanna D, et al. Tocilizumab in systemic sclerosis: focuSSced trial. Lancet Respir Med, 2020.